| Antibody–drug conjugates for cancer therapy U Hafeez, S Parakh, HK Gan, AM Scott Molecules 25 (20), 4764, 2020 | 265 | 2020 |
| Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ... British Journal of Cancer 114 (10), 1084-1089, 2016 | 138 | 2016 |
| Antibody–drug conjugates for cancer therapy AC Parslow, S Parakh, FT Lee, HK Gan, AM Scott Biomedicines 4 (3), 14, 2016 | 117 | 2016 |
| Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ... British journal of cancer 116 (12), 1558-1563, 2017 | 111 | 2017 |
| Evolution of anti-HER2 therapies for cancer treatment S Parakh, HK Gan, AC Parslow, IJG Burvenich, AW Burgess, AM Scott Cancer treatment reviews 59, 1-21, 2017 | 95 | 2017 |
| Autoantibodies may predict immune-related toxicity: Results from a phase I study of intralesional bacillus calmette–guérin followed by ipilimumab in patients with advanced … J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ... Frontiers in immunology 9, 341090, 2018 | 60 | 2018 |
| Delayed autoimmune toxicity occurring several months after cessation of anti‐PD‐1 therapy S Parakh, J Cebon, O Klein The oncologist 23 (7), 849-851, 2018 | 50 | 2018 |
| Radiolabeled antibodies for cancer imaging and therapy S Parakh, ST Lee, HK Gan, AM Scott Cancers 14 (6), 1454, 2022 | 47 | 2022 |
| Antibody-mediated delivery of therapeutics for cancer therapy S Parakh, AC Parslow, HK Gan, AM Scott Expert opinion on drug delivery 13 (3), 401-419, 2016 | 41 | 2016 |
| Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a IJG Burvenich, S Parakh, FT Lee, N Guo, Z Liu, HK Gan, A Rigopoulos, ... Theranostics 8 (15), 4199, 2018 | 40 | 2018 |
| Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma S Parakh, R Nguyen, JM Opie, MC Andrews Australasian Journal of Dermatology 58 (3), e109-e112, 2017 | 36 | 2017 |
| Outcomes of haematology/oncology patients admitted to intensive care unit at T he C anberra H ospital S Parakh, A Piggin, T Neeman, I Mitchell, P Crispin, A Davis Internal medicine journal 44 (11), 1087-1094, 2014 | 36 | 2014 |
| Multicellular effects of STAT3 in non-small cell lung cancer: Mechanistic insights and therapeutic opportunities S Parakh, M Ernst, AR Poh Cancers 13 (24), 6228, 2021 | 35 | 2021 |
| Current development of monoclonal antibodies in cancer therapy S Parakh, D King, HK Gan, AM Scott Current Immunotherapeutic Strategies in Cancer, 1-70, 2020 | 28 | 2020 |
| Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a IJG Burvenich, S Parakh, HK Gan, FT Lee, N Guo, A Rigopoulos, ST Lee, ... Journal of Nuclear Medicine 57 (6), 974-980, 2016 | 27 | 2016 |
| Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia S Parakh, HL Wong, R Rai, S Ali, K Field, J Shapiro, R Wong, L Nott, ... Journal of geriatric oncology 6 (5), 387-394, 2015 | 23 | 2015 |
| Response evaluation and survival prediction after PD-1 immunotherapy in patients with non–small cell lung cancer: comparison of assessment methods N Ayati, ST Lee, SR Zakavi, M Cheng, WFE Lau, S Parakh, K Pathmaraj, ... Journal of Nuclear Medicine 62 (7), 926-933, 2021 | 21 | 2021 |
| Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: clinical and pathologic findings S Parakh, S Gananadha, R Allen, D Yip Asian Journal of Surgery 39 (3), 144-148, 2016 | 19 | 2016 |
| Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. S Parakh, C Murphy, D Lau, JS Cebon, MC Andrews Journal of Clinical Pharmacy & Therapeutics 40 (1), 2015 | 19 | 2015 |
| Antibody drug conjugates in glioblastoma–is there a future for them? S Parakh, J Nicolazzo, AM Scott, HK Gan Frontiers in Oncology 11, 718590, 2021 | 18 | 2021 |
